# Gilgamesh Pharmaceuticals

> Neuropsychiatric drug development with a historical Ayuh Ventures investment.

## Why it is interesting

Gilgamesh illustrates a biotech path from molecule development to a strategic pharmaceutical transaction. Distinguishing an asset acquisition from a whole-company acquisition is essential when interpreting the company's history and its investors' outcomes.

## Profile

- **Latest funding:** Not publicly disclosed
- **Latest known valuation:** Not publicly disclosed
- **Total disclosed equity funding:** Not publicly disclosed
- **Stage:** N/A
- **Status:** private
- **Industries:** biotech-life-sciences, healthtech
- **Coverage:** full
- **Last updated:** 2026-11-15

## Key facts

- Named on Ayuh Ventures' official website.
- AbbVie completed its bretisilocin asset acquisition on October 17, 2025.
- No realized return or current Ayuh ownership percentage is inferred from the transaction.

## Investors in our directory

- https://venturecapitaltracker.com/fund/ayuh-ventures

**By:** [Venture Capital Tracker](https://venturecapitaltracker.com/editorial-policy)
**Last updated:** November 15, 2026

**Editorial note:** AI tools assisted with research, structure, or drafting. Venture Capital Tracker retains human editorial responsibility for factual accuracy, relevance, and source quality before publication.

---
Source: https://venturecapitaltracker.com/startup/gilgamesh-pharmaceuticals
